CC-42344

Cocrystal Pharma's investigational drug CC-42344 demonstrated exceptional antiviral activity against the highly pathogenic 2024 Texas H5N1 avian influenza strain with an EC50 of 0.003 µM.

Cocrystal Pharma is extending its Phase 2a trial for CC-42344 due to unexpectedly low influenza infection rates among participants.

Cocrystal Pharma anticipates topline results from its Phase 2a influenza A challenge study with oral PB2 inhibitor CC-42344 by year-end.

Cocrystal Pharma's broad-spectrum antiviral CC-42344 demonstrated inhibitory activity against the highly pathogenic avian influenza A (H5N1) PB2 protein in recently completed in vitro studies.